Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Cash from Financing Activities (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Cash from Financing Activities for 2 consecutive years, with -$8000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 100.48% to -$8000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.8 million, a N/A change, with the full-year FY2024 number at $59.3 million, up 900.61% from a year prior.
  • Cash from Financing Activities was -$8000.0 for Q3 2025 at Pyxis Oncology, down from $50000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $57.5 million in Q1 2024 to a low of -$8000.0 in Q3 2025.